Daxdilimab
- Generic Name
- Daxdilimab
- Drug Type
- Biotech
- CAS Number
- 2245966-28-1
- Unique Ingredient Identifier
- CNI3N6QR71
- Background
Daxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
Lupus Nephritis Market Expected to Grow as Novel Therapies Enter Clinical Trials
• The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.
• Several innovative therapies are advancing through clinical trials, including CAR-T cell treatments from companies like Allogene Therapeutics, Adicet Bio, and Caribou Biosciences, which received FDA Fast Track designations.
• Key pharmaceutical players including Aurinia Pharmaceuticals, AstraZeneca, and Roche are developing treatments such as voclosporin, anifrolumab, and obinutuzumab to address the significant unmet needs in lupus nephritis management.
Amgen Reports Strong Global Demand in Q1 2025, Bolstering Long-Term Growth Outlook
• Amgen announced positive first quarter 2025 financial results, citing strong global demand across its product portfolio and successful new product launches.
• Chairman and CEO Bob Bradway expressed confidence in Amgen's long-term growth prospects, supported by recent successful Phase 3 clinical trial results for several products.
• The biotechnology company, which employs over 28,000 people globally, continues to focus on its mission of harnessing biology and technology to combat serious diseases.
Lupus Nephritis Clinical Trial Landscape Shows Active Development
• The lupus nephritis clinical trial pipeline is robust, featuring over 30 companies developing more than 35 therapies.
• Key players like AstraZeneca, Roche, and Novartis are advancing drugs such as Anifrolumab and Ianalumab through clinical trials.
• Recent trial activities include Adicet Bio dosing the first patient in a Phase I trial of ADI-001 and Kyverna presenting updated clinical data on KYV-101.
• Various therapeutic modalities, including monoclonal antibodies and cell therapies, are being explored across different clinical stages.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath